VVOS
Vivos Therapeutics Inc
$
4.450
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.525
Open
4.120
VWAP
4.36
Vol
142.74K
Mkt Cap
29.89M
Low
4.000
Amount
621.75K
EV/EBITDA(TTM)
--
Total Shares
3.40M
EV
27.55M
EV/OCF(TTM)
--
P/S(TTM)
1.95
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
3.36M
-17.01%
-0.380
-36.67%
3.65M
-5.35%
-0.270
-32.5%
3.97M
+7.27%
-0.260
-7.14%
Estimates Revision
The market is revising No Change the revenue expectations for Vivos Therapeutics, Inc. (VVOS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 92.64%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+92.64%
In Past 3 Month
2 Analyst Rating
-12.81% Downside
Wall Street analysts forecast VVOS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 3.88 USD with a low forecast of 2.25 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
-12.81% Downside
Current: 4.450
Low
2.25
Averages
3.88
High
5.50
-12.81% Downside
Current: 4.450
Low
2.25
Averages
3.88
High
5.50
Alliance Global Partners
Scott Henry
Buy -> Neutral
downgrade
2025-05-20
Reason
Alliance Global Partners
Scott Henry
Price Target
2025-05-20
downgrade
Buy -> Neutral
Reason
Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company's visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company's Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.
Ascendiant Capital
Lucas Ward
Strong Buy
Maintains
$6.6 → $6.2
2025-04-15
Reason
Ascendiant Capital
Lucas Ward
Price Target
$6.6 → $6.2
2025-04-15
Maintains
Strong Buy
Reason
Ascendiant Capital
Lucas Ward
Strong Buy
Reiterates
$6.6
2024-11-20
Reason
Ascendiant Capital
Lucas Ward
Price Target
$6.6
2024-11-20
Reiterates
Strong Buy
Reason
Alliance Global Partners
Scott Henry
Strong Buy
Maintains
$8.25 → $6
2024-11-19
Reason
Alliance Global Partners
Scott Henry
Price Target
$8.25 → $6
2024-11-19
Maintains
Strong Buy
Reason
Alliance Global Partners analyst Scott Henry lowered the firm's price target on Vivos Therapeutics to $6 from $8.25 and keeps a Buy rating on the shares after the company reported Q3 earnings with results that were at the lower end of expectations. Results will take time to improve given the business model shift from dentists to sleep specialists, notes the firm, which expects "flattish results" in Q4 and lowered its revenue forecast for 2025.
Ascendiant Capital
Lucas Ward
Strong Buy
Maintains
$6.4 → $6.6
2024-08-20
Reason
Ascendiant Capital
Lucas Ward
Price Target
$6.4 → $6.6
2024-08-20
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Vivos Therapeutics Inc (VVOS.O) is -3.24, compared to its 5-year average forward P/E of -2.78. For a more detailed relative valuation and DCF analysis to assess Vivos Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.78
Current PE
-3.24
Overvalued PE
0.10
Undervalued PE
-5.65
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.63
Current EV/EBITDA
-2.74
Overvalued EV/EBITDA
0.57
Undervalued EV/EBITDA
-1.83
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.17
Current PS
1.58
Overvalued PS
4.39
Undervalued PS
-0.05
Financials
Annual
Quarterly
FY2025Q1
YoY :
-11.79%
3.02M
Total Revenue
FY2025Q1
YoY :
+3.51%
-3.92M
Operating Profit
FY2025Q1
YoY :
+2.68%
-3.86M
Net Income after Tax
FY2025Q1
YoY :
-72.39%
-0.45
EPS - Diluted
FY2025Q1
YoY :
+46.91%
-3.92M
Free Cash Flow
FY2025Q1
YoY :
-15.69%
44.16
Gross Profit Margin - %
FY2025Q1
-99.19
FCF Margin - %
FY2025Q1
YoY :
+16.41%
-128.12
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VVOS News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
08:47:55
Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP
2025-07-01 (ET)
2025-07-01
08:39:32
Vivos Therapeutics receives Medicare approval for VidaSleep Oral Applicance
2025-06-26 (ET)
2025-06-26
08:38:47
Vivos announces results published of OSA using Daytime-Nighttime Appliance
Sign Up For More Events
Sign Up For More Events
News
5.0
07-30NewsfilterVivos Therapeutics Adds to Management Team to Support Expansion and Growth
9.0
06-26NASDAQ.COMVOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
9.0
06-26NewsfilterNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
Sign Up For More News
People Also Watch
LEXX
Lexaria Bioscience Corp
0.837
USD
+2.07%
CLPS
CLPS Inc
0.910
USD
-2.57%
TRSG
Tungray Technologies Inc
1.650
USD
-2.02%
AIFF
Firefly Neuroscience Inc
2.770
USD
+0.73%
RENT
Rent the Runway Inc
4.750
USD
+0.21%
CXAI
CXApp Inc
0.825
USD
-0.12%
GROW
US Global Investors Inc
2.460
USD
0.00%
XBP
XBP Global Holdings Inc
0.554
USD
+9.70%
FEAM
5E Advanced Materials Inc
4.310
USD
-8.88%
FAQ
What is Vivos Therapeutics Inc (VVOS) stock price today?
The current price of VVOS is 4.45 USD — it has increased 8.27 % in the last trading day.
What is Vivos Therapeutics Inc (VVOS)'s business?
What is the price predicton of VVOS Stock?
What is Vivos Therapeutics Inc (VVOS)'s revenue for the last quarter?
What is Vivos Therapeutics Inc (VVOS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Vivos Therapeutics Inc (VVOS)'s fundamentals?
How many employees does Vivos Therapeutics Inc (VVOS). have?